Text Size

Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality

Kempen J.H.; Newcomb C.W.; Washington T.L.; Foster C.S.; Sobrin L.; Thorne J.E.; Jabs D.A.; Suhler E.B.; Rosenbaum J.T.; Sen H.N.; Levy-Clarke G.A.; Nussenblatt R.B.; Bhatt N.P.; Lowder C.Y.; Goldstein D.A.; Leiderman Y.I.; Acharya N.R.; Holland G.N.; Read R.W.; Dunn J.P.; Dreger K.A.; Artornsombudh P.; Begum H.A.; Fitzgerald T.D.; Kothari S.; Payal A.R.; Daniel E.; Gangaputra S.S.; Kaçmaz R.O.; Liesegang T.L.; Pujari S.S.; Khachatryan N.; Maghsoudlou A.; Suga H.K.; Pak C.M.; Helzlsouer K.J.; Buchanich J.M.


  • 2023
  • Ophthalmology
View publication
  • Therapeutic Area

    Other

  • Categories

    Other

  • Affiliations

    Department of Ophthalmology and Schepens Eye Research Institute, Massachusetts Eye and Ear Infirmary, and Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States; Sight for Souls, Bellevue, Washington, United States; MCM Eye Unit, MyungSung Christian Medical Center General Hospital and MyungSung Medical School, Addis Ababa, Ethiopia; Department of Ophthalmology, Addis Ababa University School of Medicine, Addis Ababa, Ethiopia; Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, United States; Center for Occupational Biostatistics and Epidemiology, University of Pittsburgh School of Public Health, Pittsburgh, PA, United States; Massachusetts Eye Research and Surgery Institution, Waltham, Massachusetts, United States; Wilmer Eye Institute, Department of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States; Department of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States; Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, United States; Portland Veteran's Affairs Medical Center, Portland, Oregon, United States; Department of Medicine, Oregon Health and Science University, Portland, Oregon, United States; Legacy Devers Eye Institute, Portland, Oregon, United States; Department of Ophthalmology, George Washington University, Washington, District of Columbia, United States; Janssen Retina Global Clinical Development, Princeton, New Jersey, United States; Department of Ophthalmology and Visual Sciences, West Virginia University, Morgantown, WV, United States; Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland, United States; Department of Ophthalmology, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania, United States; Cole Eye Institute, Department of Ophthalmology, Cleveland Clinic, Cleveland, Ohio, United States; Department of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States; Illinois Eye & Ear Infirmary, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois, United States; F.I. Proctor Foundation, Department of Ophthalmology, University of California San Francisco School of Medicine, San Francisco, California, United States; Ocular Inflammatory Disease Center, Jules Stein Eye Institute, Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States; Department of Ophthalmology and Visual Sciences, University of Alabama at Birmingham, Birmingham, Alabama, United States; Mid-Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania, United States; Department of Population, Family, and Reproductive Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States; Department of Ophthalmology, Somdech Phra Pinkloa Hospital, Royal Thai Navy, Bangkok, Thailand; Department of Ophthalmology, Chulalongkorn University, Bangkok, Thailand; Mahatme Eye Bank Eye Hospital, Maharashtra, Nagpur, India; Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, United States; Santen Inc., Emeryville, CA, United States; Siddharth Netralaya Superspecialty Eye Hospital, Karnataka, Belgaum, India; Department of Neurology, Northwell Health, Staten Island, New York, United States; University of Rochester School of Medicine & Dentistry, Rochester, New York, United States

Related Publications

Exploring Cell-Penetrating Peptides as Penetration Enhancers in Eye Drop Formulations Using a Reconstructed Human Corneal Epithelial Model

Morofuji R.; Enomoto H.; Honda T.; Oyama Y.; Ishida R.; Kudo K.; Okabe K.


Usability of an Eye Drop Delivery Aid for Single-Dose Instillation: Results from a Market Research Study

Lebrón Gutiérrez K.; Thomas S.; Martin J.L.; Dahlmann-Noor A.


Viability of European cross-border access opportunities to streamline access to ATMPs

Angelillo L.; van Steen C.; Ross-Stewart K.; Dehnen J.; Colasante W.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022